Last reviewed · How we verify
NCT03021720: SPARQLE
Satisfaction of Patients With Trans-Arterial Radial Access: Quality of Life in Uterine Fibroid Embolization Trial
NA trial testing Arterial access in Uterine Fibroid in 40 participants. Completed in 1 February 2020.
1 February 2020
Quick facts
| Lead sponsor | Mount Sinai Hospital, Canada |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | other |
| Enrollment | 40 |
| Start date | 1 November 2016 |
| Primary completion | 1 February 2020 |
| Estimated completion | 1 February 2020 |
| Sites | 2 locations across Canada |
Drugs / interventions tested
- Arterial access
Conditions studied
- Uterine Fibroid — all drugs for Uterine Fibroid →
Sponsor
Mount Sinai Hospital, Canada
Who can join
18 and older, female only, with Uterine Fibroid. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Patient satisfaction
Time frame: From date of procedure to one month after procedure
Based on visual analog scale (min 0, max 10; higher score indicates better outcome)
Sponsor's own description
Randomized trial comparing uterine fibroid embolization patient satisfaction and quality of life with femoral versus radial arterial access
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
Verify or expand the search:
- PubMed search for NCT03021720
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Arterial access
Trials testing the same drug.
- NCT04861389 — Distal Transradial Access for Primary Percutaneous Coronary Intervention in STEMI Patients · NA · unknown
Other recruiting trials for Uterine Fibroid
Currently open trials in the same condition.
- NCT07173127 — The Impact of a Novel GnRH Antagonist With Add-back Therapy for Treatment of Uterine Fibroids and Endometriosis on Hemos · NA · recruiting
- NCT06705075 — Evaluation of Uterine Fibroids by CEUS and SHAPE Pre and Post UAE · Phase 2 · recruiting
- NCT06244251 — Comparison Between Laparoendoscopic Single-site Surgery and Multi-port Laparoscopy in Treating Uterine Fibroids · NA · active not recruiting
- NCT05386615 — Post-Exablate Pregnancy Outcomes Registry Study: Exablate Treatment of Symptomatic Uterine Fibroids · recruiting
Other Mount Sinai Hospital, Canada trials
Trials by the same sponsor.
- NCT07272460 — Time Restricted-EAting for Type 2 Diabetes and MEtabolic Health: the TEA TIME Trial · NA · recruiting
- NCT07046572 — Methoxyflurane for IUD Insertion and Endometrial Biopsy · NA · recruiting
- NCT06504277 — Low Versus Standard Pressure Pneumoperitoneum on Shoulder Tip Pain · NA · recruiting
- NCT06546254 — 1% Lidocaine Paracervical Block for Endometrial Biopsy · NA · completed
- NCT06733701 — The Use of Virtual Reality Technology During Oocyte Retrieval for in Vitro Fertilization · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03021720 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mount Sinai Hospital, Canada
- Last refreshed: 23 February 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03021720.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing